TREE NEWS update: Novo Nordisk’s clinical trial showed that its Wegovy injection reduced BMI and obesity prevalence in children, the company reported. The trial results indicate the weight-loss drug’s effect extends to pediatric patients. Further details of the study were not disclosed.
Novo Nordisk trial shows Wegovy injection lowers BMI and obesity prevalence in children
The signal here is breadth rather than novelty: Wegovy's effect now extends to pediatric patients, widening the potential population the drug class can address beyond adults. That matters most for Novo Nordisk's competitive position against rival weight-loss therapies, and for pediatric obesity treatment pathways more broadly. The absence of disclosed study details — effect size, duration, safety profile — leaves the clinical picture incomplete, and whether regulators and physicians treat pediatric data as a meaningful expansion is the open question worth watching.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.